RYTM Earnings Prediction
The chart below shows how RYTM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RYTM sees a -2.16% change in stock price 10 days leading up to the earnings, and a +2.95% change 10 days following the report. On the earnings day itself, the stock moves by +4.75%. This data can give you a slight idea of what to expect for the next quarter's release.
RYTM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
33.25M
47.76%
14.35%
Gross Margin
88.49%
-0.88%
-1.54%
Operating Margin
-131.98%
-32.43%
-5.19%
Net Margin
-131.25%
-33.12%
18.30%
EPS
-0.73
-3.95%
32.73%
No Data Available
RYTM Earnings Analysis
Rhythm Pharmaceuticals, Inc. Common Stock Corporation (RYTM.O) Earnings Conference Call
Positive
IMCIVREE Revenue Growth: Net revenue from global sales in IMCIVREE continued to grow steadily and came in at $33.3 million in Q3 as compared to $22.5 million during the third quarter of last year.
Sequential Revenue Growth: On a sequential basis, Q3 revenue represents 14% growth over the second quarter of this year.
U.S. Revenue Increase: U.S. revenue in the third quarter was $23.3 million, accounting for 70% of product revenue during the quarter and an increase of 8% in U.S. sales on a sequential basis over the second quarter.
Patient Volume Increase: Driving this growth was an increase in the number of reimbursed patients on therapy and corresponding increase in volume of vials dispensed patients.
Named Patient Sales Growth: We are also seeing solid revenue contributions from named patient sales in several countries and the launches in Italy and Spain, which are still in their early phases, but progressing well.
Negative
IMCIVREE Revenue Growth: Net revenue from global sales in IMCIVREE continued to grow steadily and came in at $33.3 million in Q3 as compared to $22.5 million during the third quarter of last year.
U.S. Revenue Increase: U.S. revenue in the third quarter was $23.3 million, accounting for 70% of product revenue during the quarter and an increase of 8% in U.S. sales on a sequential basis over the second quarter of this year.
U.S. Sales Gross-to-Net Decline: Gross-to-net for U.S. sales in the third quarter decreased slightly quarter-over-quarter to 85% from 86% in the second quarter of the year.
R&D Expense Increase: R&D expenses were $37.9 million for the third quarter compared to $33.6 million during the third quarter of last year, representing a 25% increase from R&D expenses of $30.2 million in the second quarter due to a $3 million benefit recorded for changes in scope to the DAYBREAK and M&A trials during Q2.
SG&A Expense Increase: SG&A expenses were $35.4 million for the third quarter compared to $30.5 million for the same quarter last year.
RYTM FAQs
How does RYTM typically perform around its earnings report dates?
Is Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RYTM Earning Call Sentiment
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
RYTM.O
-1.8%Positive
The earnings call summary shows strong financial performance with a significant revenue increase and improved operational efficiency. The Q&A section highlights positive real-world data and growth potential in Europe and Japan, although there are minor concerns about demand pull-forward and unclear management responses. The market cap suggests a moderate reaction, and the lack of a share repurchase program is neutral. Overall, the positive elements outweigh the negatives, leading to a prediction of a 2% to 8% stock price increase.
